SMART trial shows comparable outcomes of two common TAVR devices in small aortic annulus patients

The SMART trial compared two transcatheter aortic valve replacement (TAVR) devices in patients with small aortic annulus, finding better valve performance with a supra-annular self-expanding valve. The trial included 716 low to intermediate risk patients, primarily women, with favorable outcomes at one year, favoring the Evolut PRO/PRO+/FX valve over the SAPIEN 3/3 Ultra. Both valves had similar clinical outcomes, but the self-expanding valve showed superior valve function and hemodynamics. The study’s results provide valuable information for device selection and suggest further follow-up is needed to assess long-term outcomes and durability of the valves.

Source link

error: Content is protected !!